DOCSLIB.ORG

Sodium Phosphates Injection • PACKAGING and STORAGE: Preserve in Tight Containers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sodium Phosphates Injection • PACKAGING and STORAGE: Preserve in Tight Containers Accessed from 128.83.63.20 by nEwp0rt1 on Mon Nov 28 19:59:40 EST 2011 4668 Sodium / Official Monographs USP 35 • CHLORIDE AND SULFATE, Sulfate 〈221〉 relative humidity known not to influence the results, prior to Sample: Equivalent to 0.1 g of Na2HPO4 performing the test. Acceptance criteria: Shows no more sulfate than corre- Insoluble substancesÐDissolve a portion equivalent to 10.0 sponds to 0.2 mL of 0.020 N sulfuric acid (NMT 0.2%) g of NaH2PO4 ´ H2O in 100 mL of hot water, filter through a • ARSENIC, Method I 〈211〉 tared filtering crucible, wash the insoluble residue with hot Test preparation: Equivalent to 187.5 mg of Na2HPO4 in 35 water, and dry at 105° for 2 hours: the weight of the residue so mL of water obtained does not exceed 20 mg (0.2%). Acceptance criteria: NMT 16 ppm Chloride 〈221〉ÐA portion equivalent to 1.0 g of NaH2PO4 ´ • HEAVY METALS 〈231〉 H2O shows no more chloride than corresponds to 0.20 mL of Sample stock solution: Dissolve the equivalent to 2.1 g of 0.020 N hydrochloric acid (0.014%). Na2HPO4 in enough water to make 50 mL. Analysis: Transfer 12 mL of the Sample stock solution to a Sulfate 〈221〉ÐA portion equivalent to 0.20 g of NaH2PO4 ´ 50-mL color-comparison tube (Test Preparation). Transfer H2O shows no more sulfate than corresponds to 0.30 mL of 11 mL of the Sample stock solution to a second color- 0.020 N sulfuric acid (0.15%). comparison tube containing 1.0 mL of Standard Lead Solu- Aluminum, calcium, and related elementsÐA solution tion (Monitor Preparation). Transfer 1.0 mL of Standard Lead containing the equivalent of 1.0 g of NaH2PO4 ´ H2O in 10 mL Solution and 11 mL of water to a third color-comparison of water does not become turbid when rendered slightly alka- tube (Standard Preparation). Proceed as directed for Proce- line to litmus paper with 6 N ammonium hydroxide. dure, omitting the dilution to 50 mL. Arsenic, Method I 〈211〉ÐDissolve a portion equivalent to Acceptance criteria: NMT 20 ppm 0.375 g of NaH2PO4 ´ H2O in 35 mL of water: the limit is 8 ppm. SPECIFIC TESTS Heavy metals 〈231〉ÐDissolve a portion equivalent to 1.0 g of • LOSS ON DRYING 〈731〉: Dry a sample at 130° to constant weight. NaH2PO4 ´ H2O in 20 mL of water, and add 1 mL of 3 N hydro- Acceptance criteria: See Table 1. chloric acid and water to make 25 mL: the limit is 0.002%. AssayÐDissolve about 2.5 g of Monobasic Sodium Phosphate, accurately weighed, in 10 mL of cold water, add 20 mL of a Table 1 cold, saturated solution of sodium chloride, then add phenol- Hydrate Form Acceptance Criteria phthalein TS, and titrate with 1 N sodium hydroxide VS, keep- Dried NMT 5.0% ing the temperature of the solution between 10° and 15° dur- Monohydrate 10.3%±12.0% ing the entire titration. Perform a blank determination, and make any necessary correction. Each mL of 1 N sodium hydrox- Dihydrate 18.5%±21.5% ide is equivalent to 120.0 mg of NaH2PO4. Heptahydrate 43.0%±50.0% Dodecahydrate 55.0%±64.0% . ADDITIONAL REQUIREMENTS Sodium Phosphates Injection • PACKAGING AND STORAGE: Preserve in tight containers. • LABELING: Label it to indicate whether it is dried or is the monohydrate, the dihydrate, the heptahydrate, or the » Sodium Phosphates Injection is a sterile solu- dodecahydrate. tion of Monobasic Sodium Phosphate and Diba- sic Sodium Phosphate in Water for Injection. It contains not less than 95.0 percent and not . more than 105.0 percent of the labeled amounts Monobasic Sodium Phosphate of monobasic sodium phosphate (NaH2PO4 ´ H2O) and dibasic sodium phosphate (Na2HPO4 ´ NaH2PO4 ´ xH2O (anhydrous) 119.98 7H2O). It contains no bacteriostat or other Phosphoric acid, monosodium salt, monohydrate. preservative. Monosodium phosphate monohydrate 137.99 [10049-21-5] . Packaging and storageÐPreserve in single-dose containers, Phosphoric acid, monosodium salt, dihydrate. preferably of Type I glass. Monosodium phosphate dihydrate 156.01 [13472-35-0]. LabelingÐThe label states the sodium content in terms of mil- Anhydrous [7558-80-7]. liequivalents in a given volume, and states also the phosphorus content in terms of millimoles in a given volume. Label the » Monobasic Sodium Phosphate contains one or Injection to indicate that it is to be diluted to appropriate two molecules of water of hydration, or is anhy- strength with water or other suitable fluid prior to administra- drous. It contains not less than 98.0 percent and tion and that once opened any unused portion is to be dis- carded. The label states also the total osmolar concentration in not more than 103.0 percent of NaH2PO4, calcu- mOsmol per L. Where the contents are less than 100 mL, or lated on the anhydrous basis. where the label states that the Injection is not for direct injec- tion but is to be diluted before use, the label alternatively may Packaging and storageÐPreserve in well-closed containers. state the total osmolar concentration in mOsmol per mL. LabelingÐLabel it to indicate whether it is anhydrous or is the monohydrate or the dihydrate. USP Reference standards 〈11〉Ð IdentificationÐA solution (1 in 20) responds to the tests for USP Endotoxin RS Sodium 〈191〉 and for Phosphate 〈191〉. IdentificationÐIt responds to the tests for Sodium 〈191〉 and pH 〈791〉: between 4.1 and 4.5, in a solution containing the for Phosphate 〈191〉. equivalent of 1.0 g of NaH2PO4 ´ H2O in 20 mL of water. Bacterial endotoxins 〈85〉ÐIt contains not more than 1.10 Water, Method I 〈921〉: less than 2.0% (anhydrous form); be- USP Endotoxin Units per mg of sodium phosphates. tween 10.0% and 15.0% (monohydrate); between 18.0% and Particulate matter 〈788〉: meets the requirements under 26.5% (dihydrate). For the monohydrate, the sample may be small-volume injections. ground to a fine powder in an atmosphere of temperature and Official from May 1, 2012 Copyright (c) 2011 The United States Pharmacopeial Convention. All rights reserved. Accessed from 128.83.63.20 by nEwp0rt1 on Mon Nov 28 19:59:40 EST 2011 USP 35 Official Monographs / Sodium 4669 Other requirementsÐIt meets the requirements under Injec- water. Titrate the excess base potentiometrically with 0.5 N hy- tions 〈1〉. drochloric acid VS to the first inflection point, at a pH of about Assay for monobasic sodium phosphateÐTransfer an accu- 9.2. Record the volume, A, in mL, of 0.5 N hydrochloric acid rately measured volume of Injection, equivalent to about 300 consumed. Continue the titration to the second inflection point, mg of anhydrous monobasic sodium phosphate, to a 100-mL at a pH of about 4.4, and record the total volume, B, in mL, of beaker, and dilute with water to about 50 mL. Place the elec- 0.5 N hydrochloric acid required in the titration. For a blank trodes of a suitable pH meter in the solution, and titrate with determination, transfer 15.0 mL of 0.5 N sodium hydroxide into 0.1 N sodium hydroxide VS to the inflection point to a pH of a 250-mL beaker, add 100 mL of water, and immediately titrate about 8.8. Each mL of 0.1 N sodium hydroxide is equivalent to potentiometrically with 0.5 N hydrochloric acid VS. Record the 13.80 mg of NaH2PO4 ´ H2O. volume, C, in mL, of 0.5 N hydrochloric acid consumed. Each Assay for dibasic sodium phosphateÐTransfer an accu- mL of the volume (C − A) of 0.5 N hydrochloric acid is equiva- rately measured volume of Injection, equivalent to about 300 lent to 69.0 mg of monobasic sodium phosphate (NaH2PO4 ´ mg of anhydrous dibasic sodium phosphate, to a 100-mL H2O). Each mL of the volume (B − C) of 0.5 N hydrochloric beaker, and dilute with water to about 50 mL. Place the elec- acid is equivalent to 134.0 mg of dibasic sodium phosphate trodes of a suitable pH meter in the solution, and titrate with (Na2HPO4 ´ 7H2O). 0.1 N hydrochloric acid VS to the inflection point to a pH of about 4.0. Each mL of 0.1 N hydrochloric acid is equivalent to 26.81 mg of Na2HPO4 ´ 7H2O. Sodium Polystyrene Sulfonate Benzene, diethenyl-, polymer with ethenylbenzene, sulfonated, . sodium salt. Sodium Phosphates Oral Solution Divinylbenzene copolymer with styrene, sulfonated, sodium salt. » Sodium Phosphates Oral Solution is a solution » Sodium Polystyrene Sulfonate is a cation-ex- of Dibasic Sodium Phosphate and Monobasic So- change resin prepared in the sodium form. Each dium Phosphate, or Dibasic Sodium Phosphate g exchanges not less than 110 mg and not more and Phosphoric Acid, in Purified Water. It con- than 135 mg of potassium, calculated on the an- tains, in each 100 mL, not less than 16.2 g and hydrous basis. not more than 19.8 g of dibasic sodium phos- Packaging and storageÐPreserve in well-closed containers. phate (Na2HPO4 ´ 7H2O), and not less than 43.2 LabelingÐSodium Polystyrene Sulfonate that is intended for g and not more than 52.8 g of monobasic so- preparing suspensions for oral or rectal administration may be labeled Sodium Polystyrene Sulfonate for Suspension. dium phosphate (NaH2PO4 ´ H2O). Water, Method I 〈921〉: not more than 10.0%. Packaging and storageÐPreserve in tight containers. Limit of ammonium saltsÐPlace 1 g in a 50-mL beaker, add IdentificationÐIt responds to the tests for Sodium 〈191〉 and 5 mL of 1 N sodium hydroxide, cover the beaker with a watch for Phosphate 〈191〉. glass having a moistened strip of red litmus paper on the un- Specific gravity 〈841〉: between 1.333 and 1.366.
Load more

Recommended publications
  • FLEET® Enemas Are Designed for Quick, Convenient Administration by Nurse, Patient Or Caregiver According to Instructions
    Reference Safety Information – Fleet Enema FLEET® ENEMA, A SALINE LAXATIVE FLEET® ENEMA EXTRA®, A SALINE LAXATIVE FLEET® PEDIA-LAX® ENEMA, A SALINE LAXATIVE, FLEET® ENEMA FOR CHILDREN, A SALINE LAXATIVE FLEET® enemas are designed for quick, convenient administration by nurse, patient or caregiver according to instructions. Each is disposable after a single use. COMPOSITION: FLEET® ENEMA: Each FLEET® Enema unit, with a 2-inch, pre-lubricated Comfortip®, contains 4.5 fl. oz. (133 mL) of enema solution in a ready-to-use squeeze bottle which is not made with natural rubber latex. Each enema unit delivers a dose of 118 mL, which contains 19 g monobasic sodium phosphate monohydrate and 7 g dibasic sodium phosphate heptahydrate. Each Fleet® Enema 118 mL delivered dose contains 4.4 grams sodium. FLEET® ENEMA EXTRA®: Each FLEET® Enema EXTRA® unit, with a 2-inch, pre-lubricated Comfortip®, contains 7.8 fl. oz. (230 mL) of enema solution in a ready-to-use squeeze bottle which is not made with natural rubber latex. Each enema unit delivers a dose of 197 mL, which contains 19 g monobasic sodium phosphate monohydrate and 7 g dibasic sodium phosphate heptahydrate. Each Fleet® Enema EXTRA® 197 mL delivered dose contains 4.4 grams sodium. FLEET® PEDIA-LAX® ENEMA and FLEET® ENEMA FOR CHILDREN: Each Fleet® Pedia- Lax® Enema and FLEET® Enema for Children unit, with a 2-inch, pre-lubricated Comfortip®, contains 2.25 fl. oz. (66 mL) of enema solution in a ready-to use squeeze bottle which is not made with natural rubber latex. Each enema unit delivers a dose of 59 mL, which contains 9.5 g monobasic sodium phosphate monohydrate and 3.5 g dibasic sodium phosphate heptahydrate.
    [Show full text]
  • General Properties of the Alkaline Phosphates: - Major Food and Technical Applications
    Phosphorus Research Bulletin Vol. 15 (2004) p. 85-94 General Properties of the Alkaline Phosphates: - Major Food and Technical Applications P.HOURANT Deputy Business Line Manager, Prayon S.A., Business Unit Phosphates, Rue Joseph Wauters, 144 4480 Engis, Belgium; E-mail: [email protected] INTRODUCTION The alkaline phosphates are used for many food and technical applications. Phosphates have two characteristics that explain their four main properties: buffer agent, sequestering power, dispersing power and water holding capability. Those properties allow phosphates to be used in many food and technical applications. The main food applications are meat and seafood processing, baking and processed cheese, but others such as cereals, French fries, fruits and vegetables, beverages, noodles and so on also may need the use of phosphates. On the technical side, the main applications are the detergent products, the water treatment and the metal treatment. As for the food, many other applications require phosphates such as ceramics, bone china, paper and paints,... In meat products, phosphates salts interact in a unique way to bind water with proteins and improve the tenderness in meats. Treated products will maintain their juicy appearance as well as their natural nutritional properties texture and colour. In fish and seafood products, phosphates salts allow the retention of the natural juices of frozen fish fillets, prawns, shrimps, scallops and other seafood. Phosphates also help prevent the build-up of struvite crystals in tinned tuna and crabmeat. In processed cheese, phosphates are crucially important in the production of processed cheese. These products ensure a homogeneous and uniform melt of raw cheese and product stability.
    [Show full text]
  • Phosphates' Function in Poultry Products
    [Salt/Sodium Reduction] Vol. 17 No. 8 August 2007 ww Phosphates’ Function in Poultry Products By Andrew G. Ebert, Ph.D., Contributing Editor Food-grade phosphates perform a number of functions in processed poultry products. These properties include raising pH, increasing ionic strength and reacting with protein, which improves the water-holding capacity of the functional myofibrillar protein in poultry, thereby decreasing cook-cool loss, and creating improved and uniform yields. Phosphates protect against oxidation of lipids by binding metal ions that accelerate oxidation. They protect and preserve the natural flavor and color of poultry, and they solubilize protein, which is required in producing formed and restructured products, such as delicatessen rolls and chicken nuggets. Additive effects Studies with poultry products began over 40 years ago. Early applications involved static holding in solutions containing sodium tripolyphosphate (STPP), an alkaline phosphate, and sodium hexametaphosphate (SHMP). The most-notable food-technological effects were a 6.2% increase in moisture content and a rise in pH from 6.1 to 6.6, due to the addition of phosphate. With levels of phosphates used today, a more-modest rise (0.1 to 0.3 pH units, depending upon the phosphate or blend) would be anticipated. More recent studies have shown that the use of phosphates increases the temperature required for denaturation of protein and, thus, reduces cook-cool loss, leading to an end product with greater succulence. The addition of STPP and sodium chloride (NaCl) in poultry-processing formulations has been shown to have a number of advantages. First, STPP and NaCl increase ionic strength and synergistically extract myofibrillar protein.
    [Show full text]
  • Use of Thin Layer Chromatography in Detecting the Addition and Degradation of Sodium Phosphates in Seafood Products
    USE OF THIN LAYER CHROMATOGRAPHY IN DETECTING THE ADDITION AND DEGRADATION OF SODIUM PHOSPHATES IN SEAFOOD PRODUCTS By PHILLIP BLAINE HOLMBERG A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE UNIVERSITY OF FLORIDA 2010 1 © 2010 Phillip Blaine Holmberg 2 To my parents, Eric and Helen Holmberg, and to all who nurtured my intellectual curiosity, academic interests, and sense of scholarship throughout my lifetime, making this milestone possible 3 ACKNOWLEDGMENTS I would like to thank my major advisor, Dr. Otwell, for all of his advice, support and opportunities to gain knowledge and experience. I would also like to thank my other graduate committee members, Dr. Marty Marshall and Dr. Frank Chapman. I extend a special thanks to Sven-Eric Ebeling and everyone at Chemische Fabrik Budenheim KG for their teachings and generous hospitality during my research in Germany. I thank Laura Garrido for helping me with everything along the way. I also thank Victor Garrido and all of my lab mates, past and present, Steven D’uva, Alex Fortunado, Marcus Ladd, Zach Lowenstein, Kelley Zhou, and Ivan Lozano. I thank Zina Williams for all of her help and support. Finally, I would like to thank my friends and family for all the good times and always being there for me. 4 TABLE OF CONTENTS page ACKNOWLEDGMENTS .................................................................................................. 4 LIST OF TABLES ...........................................................................................................
    [Show full text]
  • QUALITY CHOICE SINGLE SALINE ENEMA LAXATIVE Drug Facts
    QUALITY CHOICE SINGLE SALINE LAXATIVE- sodium phosphate, dibasic and sodium phosphate, monobasic, unspecified form enema CDMA Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- QUALITY CHOICE SINGLE SALINE ENEMA LAXATIVE Drug Facts Active ingredients (in each 118mL Purpose delivered dose) Dibasic Sodium Phosphate 7 g Saline laxative Monobasic Sodium Phosphate 19 g Saline laxative Use Relieves occasional constipation Warnings For rectal use only. Dosage warning Using more than one enema in 24 hours can be harmful. Ask a doctor before use if you already used a laxative for more than 1 week have kidney disease have heart problems are dehydrated are 55 years old or older are on a sodium-restricted diet Ask a doctor before using any laxative if you have abdominal pain, nausea, or vomiting a sudden change in bowel habits lasting more than 2 weeks already used a laxative for more than 1 week When using this product do not use more than directed. Serious side effects may occur from excess dosage do not use for more than 3 days Stop use and ask a doctor if you have bleeding the condtion worsens or does not improve within 7 days you have no bowel movement within 30 minutes of enema use you have symptoms of dehydration (thirstiness, dizziness, vomiting, urinating less often than normal) These symptoms may indicate a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.
    [Show full text]
  • Federal Register/Vol. 63, No. 98/Thursday, May 21, 1998/Rules and Regulations
    27836 Federal Register / Vol. 63, No. 98 / Thursday, May 21, 1998 / Rules and Regulations concludes that the proposed use of the (address above) between 9 a.m. and 4 document. Any objections received in additive is safe, that the additive will p.m., Monday through Friday. response to the regulation may be seen achieve its intended technical effect, Any person who will be adversely in the Dockets Management Branch and therefore, that the regulations in affected by this regulation may at any between 9 a.m. and 4 p.m., Monday § 178.2010 should be amended as set time on or before June 22, 1998, file through Friday. forth below. with the Dockets Management Branch List of Subjects in 21 CFR Part 178 In accordance with § 171.1(h) (21 CFR (address above) written objections thereto. Each objection shall be Food additives, Food packaging. 171.1(h)), the petition and the Therefore, under the Federal Food, documents that FDA considered and separately numbered, and each numbered objection shall specify with Drug, and Cosmetic Act and under relied upon in reaching its decision to authority delegated to the Commissioner approve the petition are available for particularity the provisions of the regulation to which objection is made of Food and Drugs and redelegated to inspection at the Center for Food Safety the Director, Center for Food Safety and and Applied Nutrition by appointment and the grounds for the objection. Each numbered objection on which a hearing Applied Nutrition, 21 CFR part 178 is with the information contact person amended as follows: listed above.
    [Show full text]
  • Federal Register/Vol. 63, No. 98/Thursday, May 21, 1998/Proposed Rules
    27886 Federal Register / Vol. 63, No. 98 / Thursday, May 21, 1998 / Proposed Rules (301) 504±0800 or delivered to the allow garments sized for a child nine PART 1616ÐSTANDARD FOR THE Office of the Secretary, Room 501, 4330 months and under and tight-fitting FLAMMABILITY OF CHILDREN'S East-West Highway, Bethesda, Maryland garments in sizes above nine months to SLEEPWEAR: SIZES 7 THROUGH 14 20814. Copies should be submitted in be sold and used as sleepwear. five copies and captioned ``Sleepwear Therefore, the Commission proposes to 1. The authority citation for part 1616 Policy Statement.'' Comments may also modify the policy statements at continues to read as follows: be filed by telefacsimile to (301) 504± 1615.64(d) and 1616.65(d) to provide Authority: Sec. 4, 67 Stat. 112, as 0127 or by e-mail to cpsc [email protected]. that infant garments (defined in the amended, 81 Stat. 569±70; 15 U.S.C. 1193. FOR FURTHER INFORMATION CONTACT: amended sleepwear standard at 16 CFR 2. Section 1616.65 is amended by Patricia Fairall, Program Manager, 1615.1(c)(1) as sized for a child nine revising paragraph (d) introductory text Office of Compliance, Consumer months and under) and ``tight-fitting'' to read as follows: Product Safety Commission, garments (defined in the amended Washington, D.C. 20207; telephone sleepwear standard at 16 CFR 1615.1(o) § 1616.65 Policy scope of the standard. (301) 504±0400, extension 1369. and 1616.2(m)) can be marketed and * * * * * SUPPLEMENTARY INFORMATION: promoted with other sleepwear. (d) Retailers, distributors, and For the reasons stated above and wholesalers, as well as manufacturers, A.
    [Show full text]
  • Federal Register/Vol. 76, No. 29/Friday, February 11, 2011
    Federal Register / Vol. 76, No. 29 / Friday, February 11, 2011 / Proposed Rules 7743 § 330.17 Deposit insurance training. (d) Definitions. (1) Account shall drug that is directed to healthcare (a) Purpose. The purpose of this mean a deposit account at a depository professionals who prescribe, administer, section is to maintain confidence in institution that is held by or offered to or dispense medications and is not Federally insured depository a customer. It includes time, demand, included in OTC drug product labeling institutions and to protect depositors by savings, and negotiable order of for consumers. FDA is issuing this requiring insured depository institution withdrawal accounts. The term does not proposed rule after a careful review of employees with authority to open include a fiduciary account as to which new data and information on the serious accounts and/or respond to customer the insured depository institution does side effects that have been associated inquiries regarding deposit insurance not, in the normal course of business, with the customary dose of OTC sodium coverage (‘‘employees’’), to complete keep records of beneficial owners of the phosphates solution (approximately 60 training on basic deposit insurance deposits in the account. grams (g) of sodium phosphates taken in principles once in any twelve month (2) New Account shall mean any two 45-milliliter (mL) doses 12 hours period. New employees must complete deposit account at an insured apart or approximately 50 g of sodium the training within 30 days of depository institution to which the phosphates taken in a 45-mL dose commencing employment. Current insured depository institution assigns a followed by a 30-mL dose 12 hours employees are required to complete the unique identifier that serves to later) for bowel cleansing prior to training within 60 days of the effective distinguish the account from other, colonoscopy.
    [Show full text]
  • UNITED STATES PATENT OFFICE 2,510,510 GERMICIDAL DETERGENT COMPOSITION Elwyn E
    Patented June 6, 1950 2,510,510 UNITED STATES PATENT OFFICE 2,510,510 GERMICIDAL DETERGENT COMPOSITION Elwyn E. Mendenhall, Pittsburgh, Pa., assignor to Economics Laboratory, Inc., St. Paul, Minn., a corporation of Delaware No Drawing. Application October 3, 1945, Serial No. 620,172 9 Claims. (CL 252-107) 2 . This invention relates to improved germicides invention are not noticeably affected by light, and germicidal detergents and water softening and do not stain the skin. They may be used compositions, and more particularly to silver with soaps, in acid, neutral or alkaline Solution, containing glassy systems of value for Such uses. and are resistant to precipitation on contact with The usefulness of silver as a germicide has 5 organic materials found in wash or other Solu long been recognized. Numerous silver-contain tions. For these reasons, and in view of the high ing compounds have been used as antiseptics, activity of the compositions, that is, high germi such as silver acetate, silver bromide, silver chlo cidal effectiveness with low concentration of sil ride, and silver citrate. Silver iodide has been ver, they are of benefit as germicides and of par used in preparing colloidal silver preparations, 10 ticular advantage in germicidal detergentS alad and silver nitrate has also been used for this as germicidal water Softening agents. and numerous other purposes. Various silver The new compositions themselves may be effec vitellin preparations have been used as antiseptics tive water softening agents and may have effec in the treatment of the eyes, nose and throat. tive detergent properties, as when the composi Most such silver compounds are possessed of 15 tions consist of complex glassy phosphates con certain undesirable characteristics which detract taining some silver and substantial proportions of from their usefulness.
    [Show full text]
  • 21 CFR Ch. I (4–1–10 Edition) § 201.307
    § 201.307 21 CFR Ch. I (4–1–10 Edition) publication of this section, with re- tainer was mistakenly used instead of spect to the marketing of uncoated the 45-mL or 90-mL container. The tablets containing potassium chloride Food and Drug Administration is lim- or other potassium salts which supply iting the amount of sodium phosphates 100 milligrams or more of potassium oral solution to not more than 90 mL (3 per tablet or with respect to liquid ounces (oz)) per OTC container because preparations containing potassium of the serious health risks associated chloride or other potassium salts which with the ingestion of larger than in- supply 20 milligrams or more of potas- tended doses of this product. Further, sium per milliliter, labeled or intended because an overdose of either oral or for human use, unless all the following rectal enema sodium phosphates can conditions are met: cause an electrolyte imbalance, addi- (1) The labeling of the drug bears the tional warning and direction state- prescription statement quoted in sec- ments are required for the safe use of tion 503(b)(4) of the Federal Food, any OTC laxative drug product con- Drug, and Cosmetic Act; and taining sodium phosphates. (2) The labeling on or within the (b) Any OTC drug product for lax- package from which the drug is to be ative or bowel cleansing use containing dispensed bears adequate information sodium phosphates as an active ingre- for its use by practitioners in accord dient when marketed as described in with the ‘‘full disclosure’’ labeling re- paragraph (a) of
    [Show full text]
  • A Comparative Review of Use of Sulphate and Phosphate Salts for Colonoscopy Preparations and Their Potential for Nephrotoxicity
    Review A comparative review of use of sulphate and phosphate salts for colonoscopy preparations and their potential for nephrotoxicity Authors Bruno Moulin1, Thierry Ponchon2 Institutions “(phosphates OR sulfates) AND cathartics [MeSH Term] 1 Nephrology Department, Strasbourg University AND kidney” restricted to humans with a cut-off date of De- Hospital, 67091 Strasbourg, France cember 31, 2016. 2 Hepatogastroenterology Department, Edouard Herriot Results Introduction of oral phosphate salts offered the Hospital, 69000 Lyon, France advantage of low intake volume and low risk of bowel irrita- tion compared to previous options. However, phosphate submitted 21.6.2017 salts have been associated with renal toxicity (acute phos- accepted after revision 28.11.2017 phate nephropathy [APN]), thought to arise due to pertur- bations of calcium and phosphate homeostasis as a conse- Bibliography quence of increases in serum phosphate. This results in high DOI https://doi.org/10.1055/a-0581-8723 | concentrations of calcium phosphate in the distal tubule Endoscopy International Open 2018; 06: E1206–E1213 and collecting ducts of the kidney, where it may precipi- © Georg Thieme Verlag KG Stuttgart · New York tate. Although APN is rare, it may lead to permanent kidney ISSN 2364-3722 damage. For this reason, phosphate salts are contraindicat- ed in vulnerable patient groups. As an alternative to phos- Corresponding author phate salts, oral sulphate salts have recently been intro- Pr. Bruno Moulin, Service de néphrologie et transplantation duced. Because sulphate absorption from the intestinal rénale, CHU de Strasbourg – Nouvel Hôpital Civil, 1, place tract is saturable, serum sulphate concentrations increase de l'Hôpital, BP 426, 67091 Strasbourg Cedex, France only minimally after ingestion.
    [Show full text]
  • And Pyrophosphates Added to Meat and Meat Products Ricardo A
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1985 Microbiological effects on poly- and pyrophosphates added to meat and meat products Ricardo A. Molins Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Agriculture Commons, Food Microbiology Commons, and the Microbiology Commons Recommended Citation Molins, Ricardo A., "Microbiological effects on poly- and pyrophosphates added to meat and meat products " (1985). Retrospective Theses and Dissertations. 12088. https://lib.dr.iastate.edu/rtd/12088 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This reproduction was made from a copy of a document sent to us for microfilming. While the most advanced technology has been used to photograph and reproduce this document, the quality of the reproduction is heavily dependent upon the quality of the material submitted. The following explanation of techniques is provided to help clarify markings or notations wliich may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting through an image and duplicating adjacent pages to assure complete continuity.
    [Show full text]